

## Product datasheet for **TL304945V**

### DNASE2B Human shRNA Lentiviral Particle (Locus ID 58511)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	DNASE2B Human shRNA Lentiviral Particle (Locus ID 58511)
Locus ID:	58511
Synonyms:	DLAD
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	DNASE2B - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_021233</a> , <a href="#">NM_058248</a> , <a href="#">NM_021233.1</a> , <a href="#">NM_021233.2</a> , <a href="#">NM_058248.1</a> , <a href="#">BC126136</a> , <a href="#">BC065182</a> , <a href="#">BC080621</a> , <a href="#">BC126138</a>
UniProt ID:	<a href="#">Q8WZ79</a>
Summary:	The protein encoded by this gene shares considerable sequence similarity to, and is structurally related to DNase II. The latter is a well characterized endonuclease that catalyzes DNA hydrolysis in the absence of divalent cations at acidic pH. Unlike DNase II which is ubiquitously expressed, expression of this gene product is restricted to the salivary gland and lungs. The gene has been localized to chromosome 1p22.3 adjacent (and in opposite orientation) to the uricase pseudogene. Two transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).